Close Menu

NEW YORK (GenomeWeb) – Gurgaon, India-based Core Diagnostics said today that it has reached an agreement with Guardant Health AMEA under which it will market Guardant's comprehensive liquid biopsy test, Guardant360, in India.

Guardant360 detects cell-free circulating tumor DNA from 73 genes in blood samples from advanced solid-tumor cancer patients, detecting the four major classes of alterations relevant for treatment selection: point mutations, indels, copy number alteration, and fusions/rearrangements.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.